Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

This study has been terminated.
(Business decision)
Information provided by (Responsible Party):
Fate Therapeutics Identifier:
First received: June 21, 2012
Last updated: September 9, 2016
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: February 2017
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)